Esperion Hopes CVOT Will Help Drive Nexletol/Nexlizet’s Market Uptake
The drugs have been slow to catch on since approval more than two years ago, but results showing reduction in cardiovascular events could help it gain traction.
The drugs have been slow to catch on since approval more than two years ago, but results showing reduction in cardiovascular events could help it gain traction.